Kikkawa et al. previously demonstrated that BCAM antibodies can be internalized into breast cancer cells, facilitating their conjugation with highly toxic agents, such as radioisotopes or systemic toxins, to develop ADCs [19]. This evidence concerns the gene BCAM and breast carcinoma.